Axon Enterprise (NASDAQ:AXON) Given New $285.00 Price Target at JMP Securities

Axon Enterprise (NASDAQ:AXONFree Report) had its price target hoisted by JMP Securities from $250.00 to $285.00 in a research note released on Tuesday morning, Benzinga reports. The firm currently has a market outperform rating on the biotechnology company’s stock.

Other analysts also recently issued reports about the stock. Barclays increased their price target on shares of Axon Enterprise from $247.00 to $296.00 and gave the company an overweight rating in a report on Tuesday, January 2nd. TheStreet raised Axon Enterprise from a c rating to a b rating in a research report on Tuesday, November 7th. Raymond James upped their price target on Axon Enterprise from $223.00 to $233.00 and gave the company an outperform rating in a report on Wednesday, November 8th. Finally, Needham & Company LLC reissued a buy rating and set a $240.00 price objective on shares of Axon Enterprise in a report on Friday, February 2nd. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Axon Enterprise currently has an average rating of Moderate Buy and an average target price of $255.36.

Get Our Latest Stock Analysis on Axon Enterprise

Axon Enterprise Price Performance

NASDAQ AXON opened at $270.98 on Tuesday. The stock has a 50-day simple moving average of $252.03 and a 200 day simple moving average of $222.56. Axon Enterprise has a twelve month low of $175.37 and a twelve month high of $271.39. The stock has a market capitalization of $20.30 billion, a PE ratio of 138.96 and a beta of 0.90. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.78 and a current ratio of 3.15.

Axon Enterprise (NASDAQ:AXONGet Free Report) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.40 by $0.31. The company had revenue of $413.60 million during the quarter, compared to analyst estimates of $393.77 million. Axon Enterprise had a return on equity of 12.63% and a net margin of 9.96%. Research analysts anticipate that Axon Enterprise will post 2.29 EPS for the current year.

Insider Buying and Selling at Axon Enterprise

In other news, insider Jeffrey C. Kunins sold 2,729 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $230.79, for a total value of $629,825.91. Following the sale, the insider now owns 233,291 shares of the company’s stock, valued at approximately $53,841,229.89. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, insider Jeffrey C. Kunins sold 2,729 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $230.79, for a total value of $629,825.91. Following the transaction, the insider now directly owns 233,291 shares of the company’s stock, valued at approximately $53,841,229.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Joshua Isner sold 260 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $230.38, for a total value of $59,898.80. Following the sale, the president now owns 356,229 shares in the company, valued at $82,068,037.02. The disclosure for this sale can be found here. Over the last three months, insiders sold 44,176 shares of company stock valued at $11,017,910. 6.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Axon Enterprise by 0.3% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 147,345 shares of the biotechnology company’s stock worth $29,320,000 after acquiring an additional 495 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Axon Enterprise by 66.4% in the second quarter. Nuveen Asset Management LLC now owns 405,773 shares of the biotechnology company’s stock valued at $79,174,000 after purchasing an additional 161,868 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Axon Enterprise by 11.5% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 63,778 shares of the biotechnology company’s stock worth $12,691,000 after purchasing an additional 6,585 shares during the last quarter. Jump Financial LLC lifted its holdings in Axon Enterprise by 672.6% during the 3rd quarter. Jump Financial LLC now owns 23,262 shares of the biotechnology company’s stock worth $4,629,000 after buying an additional 20,251 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Axon Enterprise by 28.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 726,400 shares of the biotechnology company’s stock valued at $144,546,000 after buying an additional 160,359 shares during the last quarter. Institutional investors and hedge funds own 76.52% of the company’s stock.

About Axon Enterprise

(Get Free Report)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Featured Articles

Analyst Recommendations for Axon Enterprise (NASDAQ:AXON)

Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.